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Abstract: The aim of this study was to develop topical self-microemulsifying drug 
delivery systems (SMEDDS) containing antitumor agents (bleomycin, cisplatin and 
ifosfamide) and to investigate their inhibitory potential in SMEDDS on human cervical 
cancer HeLa cells. The physicochemical properties of cytostatic drug loaded SMEDDS 
were characterized. The cytotoxicity of main components of SMEDDS was also 
investigated. Their IC50 values were determined. HeLa cells were treated by different 
concentrations of cisplatin, bleomycin and ifosfamide alone and in various SMEDDS. The 
inhibitory effect on cell growth was analyzed by MTT cell viability assay. Inflammation is 
a driving force that accelerates cancer development. The inhibitory effect of these 
antitumor agents has also been tested on HeLa cells in the presence of inflammatory 
mediators (IL-1-β, TNF-α) as an in vitro model of inflamed human cervix. Significant 
differences in the cytotoxicity of cytostatic drugs alone and in SMEDDS have been found 
in a concentration-dependent manner. The self-micro emulsifying system may potentiate 
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the effectiveness of bleomycin, cisplatin and ifosfamide topically. The effect of SMEDDS 
containing antitumor agents was decreased significantly in the presence of inflammatory 
mediators. According to our experiments, the optimal SMEDDS formulation is 1:1:2:6:2 
ratios of Isopropyl myristate, Capryol 90, Kolliphor RH 40, Cremophor RH40, Transcutol 
HP and Labrasol. It can be concluded that SMEDDS may increase the inhibitory effect of 
bleomycin, ifosfamide and cisplatin on human cervical cancer HeLa cells. Inflammation on 
HeLa cells hinders the effectiveness of SMEDDS containing antitumor agents. Our results 
might ensure useful data for development of optimal antitumor formulations. 
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1. Introduction 
Uterine and cervix carcinoma is the first cause of gynecological cancer mortality in developing 
countries [1]. Cervical cancer is well-known to be a chronic inflammatory disease of multifactorial 
etiology [2]. Antitumor agents have played an important role in cervical cancer therapy [3]. Cisplatin is 
one of the main selected antitumor agents, but the remission rate of cervical cancer in advanced stage 
by cisplatin alone is only 17%–21% [4]. In recent chemotherapy, cisplatin, bleomycin and ifosfamide 
(BIP) in combination has also been applied against inoperable cervical cancer [5]. Many active 
pharmaceutical ingredients (API) have been developed to improve the efficacy of chemotherapy [6,7]. 
Combined chemotherapy results in reduced doses of single drug, lower side effects and drug resistance [8]. 
Due to the serious side effects of these cytostatic drugs, it is necessary to develop modern drug 
delivery systems which can reduce toxicity by decreasing the dose of potent therapeutic agent [9]. 
Self-micro emulsifying drug delivery systems (SMEDDS) are widely used to improve the 
bioavailability of poorly soluble drugs by presenting and maintaining API in a dissolved state, in small 
droplets of oil [10]. Hence, it is capable of penetration through various biological barriers [11]. However, 
the topical application of these systems might also be advantageous [12]. SMEDDS are composed of a 
mixture of surfactant, co-surfactant and various oils. These delivery systems form oil-in-water emulsions 
without or upon gentle agitation. SMEDDS properties always depend on inter alia the surfactant properties 
and their mixing rates. HeLa cells are a reliable model of human cervix cancer cells [13]. 
In the present study, our aim is to develop topical SMEDDS incorporating different antitumor 
agents (bleomycin, cisplatin, and Ifosfamide) and to examine their inhibitory potential in SMEDDS in 
the presence of inflammatory mediators on human cervical cancer HeLa cells. 
2. Results 
2.1. Formulation and Evaluation of Self-Micro-Emulsifying Drug Delivery Systems 
Kolliphor RH 40 and Labrasol as surfactant, Capryol 90 or Lauroglycol FCC and Transcutol HP as 
co-surfactants were used in our experiments. Based on the results of the pseudoternary phase diagram, 
every composition formed microemulsion. The maximum microemulsion existing zones observed are 
shown in Figure 1. The distribution of droplet size is presented in Figure 2. The developed SMEDDS 
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(shown in Table 1) spontaneously formed microemulsion upon mild agitation in distillated water at 
room temperature. The percentage of transmittance and refractive index of the resulted formulation 
were found to be 976.8% ± 1.31% and 1.337% ± 0.13% indicating the transparency of these 
formulations. Moreover, the developed formulation was stable for one month at room temperature. Based 
on the average diameter sizes, composition 3 (1:1:2:6:2 ratio of Isopropyl myristate, Capryol 90, Kolliphor 
RH40 Transcutol HP and Labrasol) resulted in the smallest droplet size (78.4 nm) and the highest 
microemulsion zone. 
 
Figure 1. Pseudoternary phase diagrams of compositions 1–6, (Shaded areas represented microemulsions).  
 
Figure 2. Evaluated droplet size of SMEDDS in water via DLS measurement. Evaluated 
average droplet sizes: composition 1: 137.81 ± 1.25 nm, composition 2: 68.44 ± 1.05 nm, 
composition 3: 73.28 ± 0.95 nm, composition 4: 129.31 ± 1.95 nm, composition 5:  
149.35 ± 1.00 nm, composition 6: 76.90 ± 1.00 nm. Values are expressed as means ± SD, n = 5. 
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Table 1. Ratio of surface active agents and active pharmaceutical ingredients in formulated SMEDDS. 
Composition API (mg) 
Ratio of Surface Active Agents in SMEDDSs (Total Volume of Composition: 1 mL) 
Kolliphor RH40 Labrasol Capryol 90 Lauroglycol FCC Transcutol HP Isopropyl Myristate 
1 
0.001–0.05 Cisplatin 2 2 1 0 2 1 
0.1–5.00 Ifosfamide 2 2 1 0 2 1 
0.0005–0.05 Bleomycin sulfate 2 2 1 0 2 1 
2 
0.001–0.05 Cisplatin 2 2 1 0 4 1 
0.1–5.00 Ifosfamide 2 2 1 0 4 1 
0.0005–0.05 Bleomycin sulfate 2 2 1 0 4 1 
3 
0.001–0.05 Cisplatin 2 2 1 0 6 1 
0.1–5.00 Ifosfamide 2 2 1 0 6 1 
0.0005–0.05 Bleomycin sulfate 2 2 1 0 6 1 
4 
0.001–0.05 Cisplatin 1 1 0 1 1 1 
0.1–5.00 Ifosfamide 1 1 0 1 1 1 
0.0005–0.05 Bleomycin sulfate 1 1 0 1 1 1 
5 
0.001–0.05 Cisplatin 1 1 0 1 2 1 
0.1–5.00 Ifosfamide 1 1 0 1 2 1 
0.0005–0.05 Bleomycin sulfate 1 1 0 1 2 1 
6 
0.001–0.05 Cisplatin 1 1 0 1 4 1 
0.1–5.00 Ifosfamide 1 1 0 1 4 1 
0.0005–0.05 Bleomycin sulfate 1 1 0 1 4 1 
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Drug encapsulation efficiency was evaluated by Q. Li et al. method [14]. The encapsulation 
efficiency of our SMEDDS containing model drug was previously tested. It can be found that the 
encapsulation efficiency was satisfactory. This was the reason that these SMEDDS compositions were 
used for the formulation of these antitumor agents. 
2.2. Droplet Size and Zeta Potential Determination 
Evaluated droplet size of SMEDDS in water via DLS measurement. Evaluated average droplet 
sizes: composition 1: 137.81 ± 1.25 nm, composition 2: 68.44 ± 1.05 nm, composition 3:73.28 ± 0.95 nm, 
composition 4: 129.31 ± 1.95 nm, composition 5: 149.35 ± 1.00 nm, composition 6: 76.90 ± 1.00 nm. 
Every sample was found to be a monodisperse system. (Figure 2.) The zeta potential of compositions 
was detected to be between −5.01 ± 0.49 mV and −6.55 ± 0.099 mV. The evaluated zeta potential 
values were the following: composition 1: −5.91 ± 0.87 mV, composition 2: −5.82 ± 0.65 mV, 
composition 3: −6.55 ± 0.99, composition 4: −5.56 ± 0.32 mV, composition 5: −5.14 ± 0.71 mV, 
composition 6: −5.01 ± 0.49 mV. Results are reported as means ± SD, n = 5. 
2.3. Cell Viability Test of SMEDDS Ingredients 
Cytotoxic properties have been evaluated by MTT cell viability test. Labrasol showed the  
highest cytotoxicity on HeLa cells (IC50: 0.23 ± 0.025 v/v %), Transcutol HP was less toxic (IC50:  
3.42 ± 0.035 v/v %), and Kolliphor RH 40 was responsible for the lowest cell viability reduction (IC50: 
5.12 ± 0.085 v/v %). However, there are significant differences in the cytotoxic properties of 
surfactants in a concentration-dependent manner, the IC50 values of each examined surfactant is much 
higher than the applied concentration range in SMEDDS compositions (Figure 3). 
 
Figure 3. Cytotoxic effects of applied SMEDDS components (surfactant and  
co-surfactants) on HeLa cells determined by MTT-test. Cell viability was expressed as the 
percentage of untreated control in the function of surfactant concentration. Positive control: 
Triton X 100 (10% w/v). Values are expressed as means ± SD, n = 5.  
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2.4. Evaluation of Inhibitory Effect of SMEDDS Containing Antitumor Agent 
The inhibitory effects of cisplatin, bleomycin sulfate and ifosfamide alone and formulated in 
SMEDDS on human cervical cancer HeLa cells are depicted in Figure 4. Their calculated IC50 values 
are reported in Table 2. Based on our investigations, antitumor agents hindered the cell proliferation in 
a concentration-dependent manner. The SMEDDS as a carrier system can increase the antiproliferative 
effect of cisplatin, bleomycin sulfate and Ifosfamide. Composition 3 resulted in the highest inhibitory 
effect. The IC50 concentrations of cisplatin, blemycin and ifosfamide was mixed and incorporated in 
the compositions. (Table 2.) We found that the inhibitory effect of BIP combination was higher than 
the applied antitumor agents alone. 
 
 
Figure 4. Inhibitory effect of different SMEDDS compositions containing antitumor  
agent (bleomycin sulfate, Ifosfamide and cisplatin) evaluated by MTT test. Cell viability 
was expressed as the percentage of untreated control (HBSS). Values are expressed as  
means ± SD, n = 5.  
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Table 2. Evaluated IC50 values of antitumor agents alone and in combination incorporating 
in different SMEDDS determined by MTT cell viability assay. Values are expressed as 
means ± SD, n = 5.  
API(Bold/Compositions) IC50 (μg/mL) ±SD IC50 (μg/mL) in Presence of TNF-α, IL-1-β ±SD 
Cisplatin  16.68 0.10 25.96 0.56 
Composition 1 9.63 0.11 27.88 0.21 
Composition 2 4.81 0.21 8.69 1.00 
Composition 3 2.82 0.15 5.84 0.45 
Composition 4 11.03 0.96 9.00 0.01 
Composition 5 4.26 0.85 32.70 0.21 
Composition 6 5.35 0.32 14.29 041 
Bleomycin sulfate 4.21 0.11 5.69 0.11 
Composition 1 3.84 0.15 4.37 0.19 
Composition 2 3.99 0.50 6.70 0.32 
Composition 3 0.61 0.012 0.82 0.01 
Composition 4 4.71 0.12 6.81 0.01 
Composition 5 5.12 0.33 7.56 0.02 
Composition 6 4.93 0.22 6.33 0.01 
Ifosfamide 993.50 25.00 1936.02 5.40 
Composition 1 521.70 20.40 641.10 4.21 
Composition 2 247.30 35.60 479.00 4.52 
Composition 3 148.50 1.00 191.10 3.66 
Composition 4 607.30 10.90 823.20 0.99 
Composition 5 802.41 30.55 873.14 0.99 
Composition 6 1044.70 1.11 1098.70 1.90 
BIP 3.36 0.10 4.93 0.18 
Composition 1 2.76 0.23 3.56 0.11 
Composition 2 2.01 0.21 3.67 0.34 
Composition 3 0.33 0.05 0.95 0.09 
Composition 4 3.31 0.08 3.95 0.17 
Composition 5 2.99 0.23 4.51 0.35 
Composition 6 2.74 0.32 3.45 0.37 
2.5. Evaluation of Inhibitory Effect of SMEDDS Containing Antitumor Agent in the Presence of 
Inflammatory Mediators 
The inhibitory effect of cisplatin, bleomycin sulfate and ifosfamide alone and formulated in 
SMEDDS in the presence of IL-1-β and TNF-α on human cervical cancer HeLa cells are depicted in 
Figure 5. Their calculated IC50 values are also reported in Table 2. Our results revealed that the 
antiproliferative effect of antitumor agents in SMEDDS was decreased in the presence of inflammatory 
mediators. Significant differences of the IC50 values were determined among SMEDDS compositions. 
Inhibitory effect of Composition 3 resulted in the highest IC50 value but it was less effective in the 
presence of inflammatory mediators. The IC50 concentrations of cisplatin, blemycin and ifosfamide 
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was mixed and incorporated in the compositions. Lower IC50 values were determined in the case of the 
mixture of antitumor agents but it was less effective in the presence of inflammatory mediators. (Table 2.). 
 
 
Figure 5. Inhibitory effect of different SMEDDS compositions containing antitumor agent 
(bleomycin sulfate, ifosfamide and cisplatin) in the presence of inflammatory mediators 
evaluated by MTT test. Cell viability was expressed as the percentage of untreated control 
(HBSS). Values are expressed as means ± SD, n = 5.  
2.5. Discussion  
Cervical cancer is one of the leading causes of mortality in women worldwide. Cervical screening 
programs have decreased the incidence of cervical cancer but the role of the most effective cytostatic 
therapy with less adverse effect is inevitable [15]. In our experiment, the inhibitory effect of six 
different SMEDDS compositions containing cisplatin, bleomycin sulfate, ifosfamide and their mixture 
was investigated on human cervical cancer HeLa cells. Antitumor agents: bleomycin sulfate, cisplatin 
and Ifosfamide in monotherapy and/or in combination seems to be adequate for the treatment of 
cervical cancer [16]. However, topical application of antitumor agents might be more advantageous [17]. 
Various topically administered SMEDDS were selected as carrier systems for the formulation of 
antitumor agents in our experiments. Self-microemulsifying drug delivery systems as lipid-based 
carriers are able to increase the solubility of poorly soluble drugs, but are also capable of modifying 
the permeability of different APIs by their high surfactant content as penetration enhancers [18]. The 
toxicity and permeability of our SMEDDS ingredients were previously tested [19]. The cytotoxicity of 
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SMEDDS compositions was also investigated. It was confirmed that they were not toxic in the applied 
concentrations. The metabolic health of the cells might be maintained and inhibition of their 
proliferation was not a consequence of cytotoxicity of SMEDDS. Surfactants and co-surfactants could 
improve both the paracellular and transcellular uptake of active ingredients in vitro and increase their 
relative oral bioavailability [20]. However, many advantages of SMEDDS have been shown in oral 
administration, the enhanced biological effect of local therapy is still in focus [21]. Antitumor agent 
loaded SMEDDS systems augmented the efficacy of bleomycin sulfate, cisplatin and Ifosfamide. The 
highest inhibitory effect was reached by the application of composition 3 (1:1:2:6:2 ratio of Isopropyl 
myristate, Capryol 90, Kolliphor RH40 Transcutol HP and Labrasol). The IC50 concentrations of 
bleomycin, cisplatin and Ifosfamide were mixed and incorporated in SMEDDS. Our results showed 
that their inhibitory effect was additive and significantly more effective. The role of BIP in the 
management of advanced and recurrent carcinoma of the cervix was certified in a randomized-controlled 
study [22]. Orally administered bleomycin sulfate loaded nanostructured lipid particles were 
constructed and characterized. The in vivo study indicated that the safety and the potency of 
nanoformulation was favorable in cervical cancer cells [23]. The connection between chronical 
inflammation and cervical cancer was established [24]. Inflammation is a driving force that accelerates 
cancer development [25]. In our experiment, different SMEDDS compositions were also investigated 
in the presence of IL-1-β and TNF-α on human cervical cancer HeLa cells. Decreased inhibitory 
efficacy of these carrier systems was confirmed. This emerging evidence may indicate that 
inflammation can hinder the benefit of carrier systems. The regulation of inflammatory pathways was 
presented and the impact of external factors in the development of invasive cervical neoplastic 
transformation was also proved [26]. 
3. Experimental Section  
3.1. Materials 
Antitumor agents as Cisplatin (cis-Diammineplatinum(II) dichloride), Bleomycin sulfate, 
Ifosfamide (N,3-Bis(2-chloroethyl) tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide) were 
obtained from FLUKA Analytical Ltd. ( Seelze, Germany). Labrasol, Capryol 90, Lauroglycol FCC 
and Transcutol HP were kind gifts from Gattefossé, Lyon, France. Kolliphor RH 40 were obtained 
from BASF, Ludwigshafen, Germany. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), Dulbecco’s Modified Eagle’s Medium (DMEM), Hank’s Balanced Salt Solution (HBSS), 
phosphate buffered saline (PBS), Trypsin-EDTA, Heat-inactivated fetal bovine serum (FBS),  
L-glutamine, non-essential amino acids solution, penicillin-streptomycin were purchased from  
Sigma-Aldrich (Buchs, St Gallen, Switzerland). 96 well cell plates and culturing flasks were obtained from 
Corning, New York (NY, USA). IL-1-β, TNF-α have been purchased from Sigma-Aldrich.  
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3.2. Methods 
3.2.1. Formulation and Evaluation of Self-Micro-Emulsifying Drug Delivery Systems 
Different self-emulsifying combinations have been formulated by the water and oil dilution method 
with various previously tested tensides and co-tensides [27]. The compositions are listed in Table 1. 
Tenside components were mixed at 37 °C by Schott Tritronic dispenser (SI Analytical, Mainz, 
Germany) combined with Radelkis OP-912 magnetic stirrer (Radelkis, Budapest, Hungary). The 
applied concentrations of cytostatic drugs were dissolved in the systems at room temperature by 
permanent agitation. To evaluate any signs of phase separation, the mixtures were equilibrated for 24 h. An 
Erweka DT800 rotating paddle apparatus (Erweka Gmbh, Heusenstamm, Germany) was used to 
evaluate the efficiency of self-emulsification of different mixtures. One gram of each mixture was 
added to 200 mL of distilled water with gentle agitation condition provided by a rotating paddle at 70 rpm 
and at a temperature of 37 °C. The process of self-emulsification was visually monitored for the rate of 
emulsification and for the appearance of the produced emulsions. The visual properties registered 
against the increment of the applied surfactant component in Ternary triangular diagrams. Plotting 
points of preferential combinations were selected according to cartesian coordinate calculation. 
3.2.2. Droplet Size and Zeta Potential Determination 
Diameter of dispersed phase was investigated by a Dynamic Light Scattering device (Malvern, 
Worchetershire, UK). The cumulant Dynamic Light Scattering (DLS) method was used for 
determination of droplet size of formulated emulsions. To obtain the diffusion coefficient the intensity 
correlation function has been analyzed. The measurements have been performed by Brookhaven 
Photometer (Brookhaven, Upton, NY, USA). During the operation temperature was 25 °C, the laser 
detection angle was adjusted to 90°, Lambda (λ) to 533 nm, index to 1.334 by Particle Sizing Program 
3.1 (Malvern, Worchetershire, UK, 2000). Diameters of dispersed droplets according to the diffusion 
coefficient have been evaluated automatically by the computer program [28]. To evaluate the zeta 
potential the samples were diluted with 10 mL distilled water by gentle agitation at room temperature. 
Zeta potential of samples had been evaluated by Zetasizer NanoZS analyser (Malvern, Worchetershire, 
UK). Measurements were performed in quadruplets to obtain an average and standard deviation of  
the results.  
3.2.3. Cell Culturing 
HeLa (human cervical cancer cells) was obtained from the European Collection of Cell Cultures 
(ECACC, Public Health England, Salisbury, UK). Cells were grown in plastic cell culture flasks in 
Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich Buchs, St Gallen, Switzerland), supplemented 
with 3.7 g/L NaHCO3, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 1% (v/v) non-essential 
amino acids solution, 1% (v/v) l-glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin at 37 °C in 
an atmosphere of 5% CO2. The cells were routinely maintained by regular passaging. For cytotoxic 
and transport experiments, cells were used between passage numbers 20 and 40. The culture media 
was replaced with fresh media in every 72 h [29]. 
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3.2.4. In Vitro Cell Viability Assay 
To exclude any toxic effect of the blank SMEDDS and their components on HeLa cells, MTT cell 
viability test was used [30]. Cells were seeded on flat bottom 96-well tissue culture plates at a density 
of 104 cells/well and allowed to grow in a CO2 incubator at 37 °C for 4 days. For these studies, the 
culture medium was removed, surfactant or SMEDDS solutions were added, and the cells were 
incubated for a further 30 min. After removing the samples, another 3-h-incubation in a medium 
containing MTT at the concentration of 0.5 mg/mL followed. The dark blue formazan crystals were 
dissolved in acidic isopropanol (isopropanol: 1.0 N hydrochloric acid = 25:1). The absorbance was 
measured at 570 nm against a 690 nm reference with FLUOstar OPTIMA Microplate Reader (BMG 
LABTECH, Offenburg, Germany). Cell viability was expressed as the percentage of the untreated 
control [31]. 
3.2.5. Inhibitory Effect of Different SMEDDS Containing Antitumor Agents 
HeLa proliferation were also evaluated by using MTT cell viability assay. Cells were plated in  
96-well sterile plates, at a density of 104 cells per well in 100 mL of medium, and incubated for 3–4 h. 
Cytostatic drugs alone in cell culture medium or incorporating in SMEDDS were prepared 
immediately before use and added in a volume of 50 μL and total volume of 200 μL (with 150 mL 
fresh medium supplement) per well at final concentrations of cytostatic drugs between 5 × 10−4 and  
5 mg/mL. After 72 h the samples were removed and 100 mL of freshly diluted MTT solution at a 
concentration of 0.5 mg/mL, was pipetted into each well and the plate was incubated for 3 h at 37 °C 
in a humidified, 5% CO2 atmosphere. After a specific period, cell viability was evaluated by 
measurement of the absorbance at 520 nm, using a FLUOstar OPTIMA Microplate Reader (BMG 
LABTECH). All experiments were made in quadruplicate. Standard deviations were ≤10%. 
3.2.6. Inhibitory Effect of Different SMEDDS Containing Antitumor Agents in the Presence of 
Inflammatory Mediators 
The inhibitory effect of different SMEDDS containing cytostatic drugs was evaluated in the 
presence of inflammatory mediators on human cervical cancer HeLa cells. HeLa cells were plated in 
96-well sterile plates, at a density of 104 cells per well in 100 mL of medium, and incubated with 1.25 μL 
IL-1-β (0.1 μg/μL) and 3.75 μL TNF-α (0.1 μg/μL) for 3–4 h. After ignition, the previously described 
HeLa cell proliferation test was used. 
3.2.7. Statistical Analysis 
Data were analyzed using SigmaStat (version 3.1; SPSS, IBM Inc, New York, NY, USA) and 
presented as means ± SD. Comparison of groups was performed by one-way ANOVA. This ANOVA 
was used to compare the differences of each values belong to certain concentrations in MTT. We 
marked the significant differences with asterisks in figures. After that, the results among the groups 
were presented by Tukey’s test. Differences were regarded as significant in case of p < 0.05. All 
experiments were carried out in triplicates and repeated at least three times. 
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4. Conclusions 
It can be concluded that topically administered self-microemulsifying drug delivery systems 
containing different antitumor agents may provide an alternative treatment for cervical cancer. 
Inflammatory mediators can hinder the efficacy of therapy. Our results might provide useful data for 
development of optimal antitumor formulations. 
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